alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 7,501–7,525 of 10,985 studies · free to read (page 301 of 440) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Differential neurocognitive network perturbation in amnestic and aphasic Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurology 2020-01-22

Despite the presumptive common underlying neuropathology of amyloid plaques and neurofibrillary tangles, the 2 groups displayed 2 different patterns of network perturbation, each concordant with the clinical presentation and the anatomy of neurodegeneration. 2 key findings →

Participants: 14 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Genomics 2007-04-16

The epsilon(4) allele of APOE confers a two- to fourfold increased risk for late-onset Alzheimer's disease (LOAD), but LOAD pathology does not all fit neatly around APOE. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Proceedings of the National Academy of Sciences of the United States of America 1997-08-01

Apolipoprotein E (apoE) is associated with several classes of plasma lipoproteins and mediates uptake of lipoproteins through its ability to interact with specific cell surface receptors. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Reelin signaling antagonizes beta-amyloid at the synapse

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2009-09-02

Abnormal processing of the amyloid precursor protein (APP) and beta-amyloid (Abeta) plaque accumulation are defining features of Alzheimer disease (AD), a genetically complex neurodegenerative disease that is characterized by progressive synapse loss and neuronal cell death. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Regional Overlap of Pathologies in Lewy Body Disorders

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of neuropathology and experimental neurology 2017-03-01

Lewy body disorders (LBD) are common neurodegenerative diseases characterized by the presence of aggregated α-synuclein in Lewy bodies and Lewy neurites in the central and peripheral nervous systems. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice

✓ Peer-reviewed alzhub usefulness score 44 out of 100. The Journal of biological chemistry 2015-07-10

Alzheimer disease (AD) is characterized by the extracellular accumulation of amyloid β (Aβ), which is accompanied by a robust inflammatory response in the brain. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Effect of Multidomain Interventions on Global Cognition, Symptoms of Depression and Apathy - A Pooled Analysis of Two Randomized Controlled Trials

✓ Peer-reviewed alzhub usefulness score 44 out of 100. The journal of prevention of Alzheimer's disease 2022-01-01

Cardiovascular risk factors and lifestyle factors are associated with an increased risk of cognitive decline and dementia in observational studies, and have been targeted by multidomain interventions. 5 key findings →

Participants: 4,162 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effect of Individual Virtual Reality Cognitive Training Programs on Cognitive Function and Depression in Middle-Aged Women: Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 44 out of 100. JMIR mental health 2023-10-25

These programs are considered beneficial nonpharmacological cognitive training interventions for middle-aged women at high risk of cognitive impairment. 1 key finding →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Design and Methods of the Early Age-Related Hearing Loss Investigation Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2024-06-01

After its completion in 2028, the EARHLI trial should offer evidence on the effect of hearing treatment versus a health education control on cognitive performance, social engagement, and brain organization/connectivity in 55- to 75-year-old community-dwelling adults with early ARHL and amnestic mild cognitive impairment. 2 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Personalized Integrated Care Promoting Quality of Life for Older People: Protocol for a Multicenter Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 44 out of 100. JMIR research protocols 2023-07-24

The study protocol is part of a project approved and funded by the European Commission Horizon 2020 (grant agreement number 875221). 3 key findings →

Participants: 558 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer disease and associated disorders 2009-10-01

The groups of individuals who agreed to participate in the imaging substudies of AD trials were remarkably comparable to the comparison groups at baseline on a wide range of demographic and clinical measures; there seems to be a minimal effect of self-selection bias. 4 key findings →

Participants: 166 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Intermittent fasting attenuates lipopolysaccharide-induced neuroinflammation and memory impairment

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of neuroinflammation 2014-05-06

Our results suggest that IF induces adaptive responses in the brain and periphery that can suppress inflammation and preserve cognitive function in an animal model of systemic bacterial infection. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Blood-Brain Barrier Dysfunction Precedes Cognitive Decline and Neurodegeneration in Diabetic Insulin Resistant Mouse Model: An Implication for Causal Link

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Frontiers in aging neuroscience 2017-12-01

Diabetic insulin resistance and pro-diabetic diet are reported to increase dementia risk through unknown mechanisms. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Nutrition and risk of dementia: overview and methodological issues

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Annals of the New York Academy of Sciences 2016-03-01

After two decades of research on nutrition and dementia there is strong evidence for preventive effects of vitamin E, B vitamins, and n-3 fatty acids and deleterious effects of saturated fat on dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain

✓ Peer-reviewed alzhub usefulness score 44 out of 100. JCI insight 2019-09-19

Insulin resistance associates with increased risk for cognitive decline and dementia; however, the underpinning mechanisms for this increased risk remain to be fully defined. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Youthful memory capacity in old brains: anatomic and genetic clues from the Northwestern SuperAging Project

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of cognitive neuroscience 2013-01-01

The Northwestern University SuperAging Project recruits community dwellers over the age of 80 who have unusually high performance on tests of episodic memory. 1 key finding →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The relationship between fMRI activation and cerebral atrophy: comparison of normal aging and alzheimer disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. NeuroImage 2000-03-01

Functional MRI has recently been used to examine activation associated with aging and dementia, yet little is known regarding the effect of cerebral atrophy on fMRI signal. 5 key findings →

Participants: 16 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed